Table 3.
Tumor responses (N = 30)
Responses | Toripalimab and doxorubicin | |
---|---|---|
No | % | |
CR | 1 | 3.3 |
PR | 10 | 33.3 |
SD | 13 | 43.3 |
PD | 6 | 20 |
ORR | 11 | 36.7 |
DCR | 24 | 80 |
Median PFS | 8 months | |
PFR 3 months | 80 | |
PFR 6 months | 63.3 |
CR, complete response; DCR, disease control rate; ORR, objective response rate; PD, progressive disease; PR, partial response; PFR, progression-free rate; PFS, progression-free survival; SD, stable disease.